{
    "clinical_study": {
        "@rank": "168316", 
        "acronym": "THINAS", 
        "arm_group": [
            {
                "arm_group_label": "IV thyroxin", 
                "arm_group_type": "Experimental", 
                "description": "IV thyroxin"
            }, 
            {
                "arm_group_label": "control IV saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "IV saline"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will explore whether supplementation with thyroid hormones in the set-up of\n      asthma exacerbation could improve the clinical outcomes.\n\n      The study will include adults admitted to Rambam health care campus for moderate to severe\n      Asthma exacerbation.\n\n      The study is a prospective, randomized, double-blind, placebo-controlled, clinical trial.\n      Patients will be randomized on admission to receive treatment with intra-venous thyroxine\n      (100mcg once on admission and additional 100mcg after 12 hours) or placebo. The study\n      treatment will be given only after the initial bronchodilator therapy, oxygen and informed\n      consent are given. The primary endpoint is the time to return of the peak expiratory flow\n      (PEF) rate to normal values or personal base line."
        }, 
        "brief_title": "Thyroid Hormones Treatment in Asthma Exacerbation", 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  Known Asthma\n\n          -  The exacerbation is defined as moderate or severe.\n\n          -  Not currently enrolled as an active participant in another clinical trial of a\n             medical therapy or device.\n\n          -  The patient or first degree family relative (in cases where the patient is intubated)\n             has authorized his/her consent to participate in this trial. The patient will be\n             asked to give his consent only after initial bronchodilator therapy\n\n        Exclusion Criteria:\n\n          -  60 years of age or older\n\n          -  Known thyroid disorders\n\n          -  Subject where thyrotoxicosis is suspected\n\n          -  Known heart disease\n\n          -  Heart rate > 140"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086799", 
            "org_study_id": "354-13CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "IV thyroxin", 
                "description": "N/A", 
                "intervention_name": "IV thyroxin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "elthyroxin", 
                    "thyroxin", 
                    "euthrux"
                ]
            }, 
            {
                "arm_group_label": "control IV saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "thyroid hormones", 
            "treatment", 
            "asthma exacerbation"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "g_berger@rambam.health.gov.il", 
                "last_name": "gidon berger, MD", 
                "phone": "972 502061166"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "31096"
                }, 
                "name": "Rambam health care campus"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Is There a Role for Thyroid Hormones Treatment in the Set-up of Acute Moderate to Severe Asthma Exacerbation", 
        "overall_contact": {
            "email": "g_berger@rambam.health.gov.il", 
            "last_name": "gidon berger, MD", 
            "phone": "972 502061166"
        }, 
        "overall_contact_backup": {
            "email": "nizar.andria@gmail.com", 
            "last_name": "nizar andria, MD", 
            "phone": "972 502062851"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the time to return of the PEF rate to normal values or personal base line.", 
            "measure": "time to normalization of PEF (peak expiratory flow)", 
            "safety_issue": "No", 
            "time_frame": "one week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tLength of stay (in cases of hospitalization in the internal medicine departments) or length of intubation (in cases of hospitalization in the MICU).", 
                "measure": "Length of stay", 
                "safety_issue": "Yes", 
                "time_frame": "one week"
            }, 
            {
                "description": "Time to oxygen saturation > 95% (while breathing spontaneously and without oxygen supplements)", 
                "measure": "Time to oxygenation", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }, 
            {
                "description": "Time to normalization of heart rate", 
                "measure": "heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "one week"
            }, 
            {
                "description": "Time to normalization of respiratory rate", 
                "measure": "respiratory rate", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }
        ], 
        "source": "Rambam Health Care Campus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rambam Health Care Campus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}